Risks and Opportunities of AI in Clinical Drug Development

Due to COVID-19, the event has been postponed until 2021. Details forthcoming.

Where will the AI revolution take pharmaceutical science?

Conference Co-Chairs: Demissie Alemayehu, Pfizer Inc. and David Madigan, Columbia University

The Pfizer/ASA/Columbia University Symposium on Risks and Opportunities of AI in Clinical Drug Development is an event jointly sponsored by Pfizer Inc., the American Statistical Association (ASA), and the Statistics Department and Data Science Institute at Columbia University.

Our world increasingly relies on data and computing to create knowledge, to make critical decisions, and to better predict the future. Data science has emerged to support these data-driven activities by integrating and developing ideas, concepts, and tools from computer science, engineering, information science, statistics, and domain fields. Data science now drives fields as diverse as biology, astronomy, material science, political science, and medicine—not to mention vast tracts of the global economy, key government activities, and quotidian social and societal functions.

The pharmaceutical enterprise has been slower to respond, especially to the rapid developments in AI, but tectonic shifts are underway in approaches to the discovery, development, evaluation, registration, monitoring, and marketing of medicines for the benefit of patients and the health of the community.

Learn More

Featured Speakers




Click on the images to view speaker bios

AIPM2020 Connect

Subscribe to receive updates from the AIPM Conference